Microfluidics is the science and engineering of controlling small volumes of fluid, usually inside channels between 10 and 500 micrometers wide, to mix, separate, or analyze samples at a miniaturized scale. In medical devices, microfluidic systems form the core of lab-on-a-chip diagnostics, point-of-care test cartridges, and precision drug delivery components that process microliter or nanoliter sample volumes.
What is Microfluidics?
Microfluidics sits at the intersection of fluid mechanics, materials science, and analytical chemistry. At the scale microfluidic devices operate, surface tension and viscosity dominate fluid behavior instead of inertia, so flow stays laminar and predictable. That predictability lets a chip route, split, and combine tiny fluid volumes with repeatable precision.
In a medical device program, microfluidics usually shows up as the core of a diagnostic cartridge, a lab-on-a-chip (LOC) platform, or a microdosing component inside a drug delivery system. It typically enters development during early feasibility work, when a team decides whether a benchtop assay can be miniaturized into a disposable format for point-of-care or near-patient testing.
Why Microfluidics matters in medical device development
Accuracy at this scale is unforgiving. A microfluidic diagnostic cartridge that mishandles a few microliters of sample can shift an assay result from negative to positive, so channel geometry, surface chemistry, and reagent placement all carry patient safety weight.
Regulatory bodies treat microfluidic IVD cartridges as diagnostic devices, not lab curiosities. Depending on the market, a chip-based assay may fall under EU IVDR 2017/746 or FDA’s 510(k) and de novo pathways, each requiring analytical and clinical performance data tied to the specific chip design and lot.
Cost and timeline risk show up early. Prototypes built in PDMS (polydimethylsiloxane) are cheap and fast to iterate, but rarely transfer to production. Teams that delay the switch to an injection-moldable polymer often discover late that channel tolerances, bonding methods, or optical clarity do not hold up at manufacturing scale, forcing a redesign that stalls a submission.
Audit exposure follows the same thread. Because chip geometry affects assay performance, design verification records under ISO 13485 and process validation data under 21 CFR Part 820 need to trace cleanly from requirements to test data, with no gaps an auditor can catch.
Key components of a microfluidic device
A microfluidic system is built from a small set of physical building blocks, each with its own manufacturing and validation considerations:
- Substrate material: PDMS for prototyping; cyclic olefin copolymer (COC), cyclic olefin polymer (COP), PMMA, or glass for production, chosen for optical clarity, chemical compatibility, and moldability.
- Microchannel network: etched, molded, or laser-ablated pathways that route sample and reagent, sized to control flow rate and mixing behavior.
- Fluid control elements: passive capillary structures or active components such as micropumps and microvalves that move fluid without operator intervention.
- Detection interface: optical, electrochemical, or other sensing elements that convert a chemical or biological reaction into a measurable signal.
- Cartridge housing and interconnects: the outer shell and ports that interface with a reader instrument or handheld device.
Production methods include injection molding and hot embossing for volume manufacturing, with soft lithography reserved for early prototyping. Because these devices contact patient or specimen fluid, contact materials are evaluated under ISO 10993 biocompatibility testing, and manufacturing typically runs inside classified cleanroom environments per ISO 14644. Embedded software that interprets results falls under IEC 62304, and IVD labeling follows the ISO 18113 series.
Common challenges and best practices
Air bubble entrapment is one of the most persistent problems in microfluidic design. A single trapped bubble can block a channel or distort an optical reading, so degassing steps and vent-designed channel geometry are standard mitigations.
Surface fouling and wettability drift cause a related headache. Proteins or cells can adsorb to channel walls over time, changing flow behavior between the first and the hundredth test run. Surface treatments and coatings help, but need verification across the device’s full shelf life, not just at time zero.
Scaling from a PDMS prototype to a production-ready polymer is where many programs lose the most time. Molding tolerances behave differently than lab-bench fabrication, and a channel that worked in soft lithography may need redesigning to injection-mold reliably. Bringing design-for-manufacturing input in during early feasibility, not after verification testing, avoids a late-stage scramble.
Batch-to-batch variation in molded parts can erode assay performance. Tight statistical process control on critical dimensions, with lot-level verification testing, keeps that variation from reaching the clinic undetected.
How SJML helps with Microfluidics
SJML’s technology portfolio includes microfluidics and lab-on-a-chip platforms as a core capability area, alongside its broader electromechanical design and manufacturing services. Its engineering teams work across mechanical, electronics, embedded software, and systems design, carrying a chip concept from feasibility through design verification and design transfer. On the manufacturing side, SJML operates classified cleanrooms and medical-grade plastics processing, with process validation built around IQ/OQ/PQ and a quality system aligned to ISO 13485 and applicable FDA and EU MDR/IVDR requirements. SJML has also supported point-of-care and microfluidics IVD platform programs.
Talk to SJML’s engineering team →
Frequently asked questions
Microfluidics is used to build lab-on-a-chip diagnostic cartridges, point-of-care testing platforms, wearable biosensors, and precision drug delivery components. It lets a device process microliter or nanoliter fluid volumes to run assays or deliver doses that would otherwise require full laboratory equipment.
Microfluidic channels typically range from about 10 to 500 micrometers wide, roughly the width of a human hair or narrower. At that scale, surface tension and viscosity dominate fluid behavior instead of inertia, keeping flow laminar and predictable rather than turbulent, which is what allows precise, repeatable dosing and mixing on a single chip.
Early prototypes commonly use PDMS because it is fast and inexpensive to mold in a lab. Production devices typically shift to cyclic olefin copolymer (COC), cyclic olefin polymer (COP), PMMA, or glass, chosen for optical clarity, chemical resistance, and compatibility with injection molding.
Yes, in most cases. A microfluidic cartridge intended to diagnose, screen, or monitor a condition is regulated as an in vitro diagnostic device, typically under EU IVDR 2017/746 or FDA 510(k) and de novo pathways, with analytical and clinical performance data required for the specific chip and lot.
Microfluidics is the underlying science of controlling small fluid volumes inside narrow channels. Lab-on-a-chip (LOC) refers to an actual device built on that science, one that integrates multiple laboratory functions, such as sample preparation, mixing, and detection, onto a single microfluidic chip, usually paired with a reader instrument.
Related terms
- Lab-on-a-Chip (LOC)
- Point-of-Care (POC) Diagnostics
- In Vitro Diagnostic (IVD) Device
- Design Verification
- ISO 14971 Risk Management
